Vast Therapeutics said today that it finished a Series A round with investment from Japan-based Shionogi & Co. The company plans to use the round’s proceeds to bring their nitric oxide powder technology through preclinical testing and first-in-human clinical safety and efficacy trials. Vast Therapeutics’ technology, which was in-licensed from the University of North Carolina at […]